Literature DB >> 31238182

Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis.

Masato Kono1, Yuiko Fujita2, Kenichiro Takeda2, Koichi Miyashita2, Akari Tsutsumi2, Takeshi Kobayashi2, Yoshihiro Miki2, Dai Hashimoto2, Noriyuki Enomoto3, Yutaro Nakamura3, Takafumi Suda3, Hidenori Nakamura2.   

Abstract

BACKGROUND: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare form of idiopathic interstitial pneumonias (IIP) and may have other patterns of interstitial lung disease (ILD) in the lower lobe, such as usual interstitial pneumonia (UIP). However, the clinical significance of lower-lobe ILD in patients with IPPFE is unclear.
METHODS: A retrospective review of 40 consecutive patients with clinically diagnosed IPPFE in our institution from 2005 to 2016 was conducted. The presence of lower-lobe ILD on high-resolution computed tomography (HRCT) was assessed and classified into UIP or non-UIP pattern according to a modification of diagnostic criteria for idiopathic pulmonary fibrosis. Clinical characteristics and prognostic factors were evaluated.
RESULTS: Among the 40 patients with IPPFE, 21 (53%) had lower-lobe ILD, including 13 with UIP pattern and 8 with non-UIP pattern. Patients with IPPFE who had lower-lobe ILD had significantly older age, higher frequency of fine crackles, higher serum KL-6 level, lower residual volume (RV), and lower total lung capacity (TLC) than those without lower-lobe ILD. In addition, those with lower-lobe ILD, especially UIP pattern, had a significantly poorer survival than those without lower-lobe ILD (log-rank test; p = 0.014, p < 0.001, respectively). Multivariate Cox proportional hazards regression analysis revealed that low %forced vital capacity (%FVC) at baseline and coexistence of UIP pattern were significantly associated with poor prognosis in patients with IPPFE.
CONCLUSIONS: The coexistence of lower-lobe ILD on HRCT, especially the UIP pattern, may predict poor survival in patients with IPPFE.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  High-resolution computed tomography; Interstitial lung disease; Pleuroparenchymal fibroelastosis; Prognostic factor; Usual interstitial pneumonia

Year:  2019        PMID: 31238182     DOI: 10.1016/j.rmed.2019.06.018

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

Review 1.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

2.  Pleuroparenchymal fibroelastosis-like lesions in patients with interstitial pneumonia diagnosed by multidisciplinary discussion with surgical lung biopsy.

Authors:  Hiromitsu Sumikawa; Takeshi Johkoh; Ryoko Egashira; Hiroaki Sugiura; Yasuhiko Yamano; Kensuke Kataoka; Yasuhiro Kondoh; Hiroaki Arakawa; Masahisa Nakamura; Akihiro Kuriu; Katsuyuki Nakanishi; Noriyuki Tomiyama
Journal:  Eur J Radiol Open       Date:  2020-12-11

3.  Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia.

Authors:  Keishi Sugino; Hirotaka Ono; Hiroshige Shimizu; Takeyuki Kurosawa; Keiko Matsumoto; Masahiro Ando; Kiyoshi Mori; Eiyasu Tsuboi; Sakae Homma; Kazuma Kishi
Journal:  ERJ Open Res       Date:  2021-03-01

4.  Pleuroparenchymal fibroelastosis in Korean patients: clinico-radiologic-pathologic features and 2-year follow-up.

Authors:  Jae Ha Lee; Eun Jin Chae; Joon Seon Song; Miae Kim; Jin Woo Song
Journal:  Korean J Intern Med       Date:  2020-02-24       Impact factor: 2.884

5.  A proposed prognostic prediction score for pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Takato Ikeda; Takuto Miyamura; Yusuke Ueda; Yuji Yoshida; Hisako Kushima; Masaki Fujita; Takashi Ogura; Kentaro Watanabe; Hiroshi Ishii
Journal:  Respir Res       Date:  2021-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.